Alchemia establishes level 1 ADR program
Friday, 20 August, 2004
Brisbane biotech Alchemia (ASX: ACL) has taken the first step towards a NASDAQ listing, announcing it will be establishing a Level One American Depositary Receipt (ADR) program in coming months.
Managing director Dr Tracie Ramsdale said a NASDAQ listing was a natural extension of the company’s increasing focus on the United States, which was the primary market for its future products.
Earlier this month, Alchemia completed the scale-up of the manufacturing process for its synthetic heparin, which it is developing with partners Dow Chemical and American Pharmaceutical Partners.
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
Stem cell experiments conducted in space
Scientists are one step closer to manufacturing stem cells in space — which could speed up...
